First Targeted Treatment for Grade 2 IDH-Mutant Glioma
Servier Canada announced the approval and commercial availability of VORANIGO™ (vorasidenib tablets), the first targeted therapy for the treatment of Grade 2 isocitrate dehydrogenase (IDH)-mutant glioma in adults and pediatric patients aged 12 years and older, following surgery. VORANIGO™ offers glioma patients the convenience of a once-daily oral treatment, providing them with an opportunity to actively manage their disease. Canada is the second country after the United States to receive regulatory authorization for VORANIGO™. Gliomas are the second-most common type of cancer in Canadians under 40 years old and the second-most common cause of cancer-related deaths in this group.1 These slow-growing brain tumours spread within the brain leading to disruptions in neurological function, seizures, and cognitive impairment. Diffuse gliomas with IDH mutations represent the most common malignant primary brain tumours diagnosed in adults younger than 50 years of age. They…

